Diabetes News

Adults who lose any amount of weight 1 year after being diagnosed with type 2 diabetes are more likely to achieve diabetes remission than those who gain weight, according to study data published in PLOS Medicine.

Gabapentinoid use has continued to increase in the last several years despite a “dearth of evidence” that supports the drug’s use, according to researchers.

Susan Weiner, MS, RDN, CDCES, FADCES, talks with Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, about nuances of using SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes, and a therapy for delaying type 1 diabetes onset.

Pancreatic diabetes may be as prevalent as type 1 diabetes, but knowledge of the disease is lacking. Several research programs are working to change that.

The risk for developing type 2 diabetes is substantially higher for adolescents with overweight or obesity and an HbA1c of at least 6.1% compared with those with an HbA1c of 5.5% or less, according to study data.

In the latest installment of Healio’s diversity, equity and inclusion video series with the ASGE, Catherine T. Hudson, MD, addressed how to combat emerging stigma around new anti-obesity medications such as glucagon-like peptide agonists.

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were associated with lower risk for cardiovascular events in type 2 diabetes, with or without metabolic dysfunction-associated steatotic liver disease.

Mothers with type 1 or type 2 diabetes have increased risks for having children with a congenital heart defect, according to a study published in JAMA Network Open.

Adults with type 2 diabetes who use GLP-1 receptor agonists do not have an increased short-term risk for pancreatic cancer, according to findings published in JAMA Network Open.

Glucagon-like peptide 1 receptor agonists significantly lowered the risk for colorectal cancer in patients with type 2 diabetes compared with other diabetes medications, according to a research letter in JAMA Oncology.